Wild Card: Building and investing in game-changing companies

EIT Health’s Wild Card is an open innovation programme for people who are not afraid to defy convention, take a risk, and with our help, create products and services that could change people’s lives.

We provide world-class training and mentoring to teams and individuals with bold healthcare solutions. We build and invest up to €1.5 million (grant-for-options) in two of the most promising ventures, so that together we can break new ground, push boundaries and troubleshoot some of Europe’s healthcare greatest challenges.

Applications for Wild Card 2022 will open soon. Register for email updates so we can notify you when the programme opens, and be amongst the first to apply.

Get updates

How Wild Card works

2022 Challenge: Children's Health

You have the chance to change the course of your future, and to create a healthcare solution that could transform people’s lives. Are you up to the challenge?

Our 2022 Challenge is offered in partnership with Hospital Sant Joan de Déu, and aims to create children-centric innovations — as opposed to a common adaptation of innovations designed for adults.

Stay tuned for the final details of the 2022 challenge.

Meet the Wild Cards

Discover the ventures that EIT Health’s Wild Card programme has invested in. Be inspired by the founders who started off like you and built their new company through the Wild Card journey.

  • NaturaLens

    2021 Selected Venture

    A comfortable extended wear natural contact lens for managing myopia in dry eye patients.

    There is an urgent need for novel cost-effective and non-invasive approaches for management of myopia and dry eye to avoid visual impairment and blindness. Our solution, a bioengineered natural contact lens (NaturaLens), can help address this underserved need.

    Team NaturaLens is developing a Natural Contact Lens made from the same material as the human eye that can help manage myopia in dry eye patients.

    "The EIT-Health Wild Card helped us better understand the need, examine our assumptions towards developing a solution for addressing a major underserved need in eye and vision care."

    Read Bio
  • PeriVision

    2021 Selected Venture

    A portable and AI-based perimetry device for 70% faster, patientfriendly and much more cost-efficient glaucoma patient monitor.

    PeriVision wants to reimagine glaucoma monitoring to benefit patients and doctors alike by offering a portable and Al-based perimetry device for 70% faster, patient-friendly and much more cost-efficient glaucoma patient monitoring.

    “The trend towards democratized and decentralized access as well as telehealth solutions is already well under way. We want to shape this future in glaucoma care. In this context, the Wild Card program helped us to understand who benefits most from our solution and how we build a sustainable business around that.”

    Visit PeriVision's website Read Bio
  • Orbit Health

    2020 Selected Venture

    A device-agnostic Digital Therapeutic (DTx) to enable personalized treatment of Parkinson’s Disease.

    Orbit has developed Neptune, a device-agnostic Al solution regulating treatment dosage for Parkinson's disease patients, restoring patient function and quality of life. Neptune offers to patients up to 5 extra symptom-free hours per day. 

    “Our solution equips clinicians with reliable, continuous, and objective symptom insights that are easy to access to effectively personalise treatments for each patient. Wild Card accelerated our understanding of how our solution fits in the market”

    Visit Orbit's website Read Bio
  • MiMARK

    2020 Selected Venture

    Endometrial cancer diagnosis – easy, quick, accurate and less costly diagnostic kit.

    MiMARK sets to provide in vitro diagnostic tool based on the determination of 5 protein biomarkers in uterine fluid samples to provide a diagnosis to 100% of patients, to rule out endometrial cancer with great specificity, and provide information on a histological subtype of the tumour to guide surgical treatment.

    "With our solution, we will change the standard of care for endometrial cancer by providing innovation in diagnostic technology at an early stage and without the need for invasive and uncomfortable procedures. The Wild Card programme has been fundamental in accelerating our development."

    Visit MiMARK's website Read Bio
  • Abtrace

    2019 Selected Venture

    Abtrace is using artificial intelligence to tackle AMR- perhaps the greatest global health threat of our time.

    Every use of an antibiotic comes with a risk that resistance might develop. Abtrace is using artificial intelligence to tackle AMR perhaps the greatest global health threat of our time.

    “The process is tough and thorough but, in the end, the Wild Card programme gives you the freedom to really challenge the boundaries of what is considered possible today. It’s an exciting opportunity that brought together an extraordinary team of mentors who are brilliant, very experienced and really enthusiastic.”

    Visit Abtrace's website Read Bio
  • Smart4Diagnostics

    2019 Selected Venture

    Digital blood samples – changing medical diagnostics from a trust-based system into an accurate, evidence-based system.

    Digital innovations are taking diagnostics from a trust-based system into an accurate, evidence-based system. Smart4Diagnostics closes the data gap between blood collection and lab analysis.

    “The future of healthcare is in essence a data driven future. The question is, who is producing the data? Who is owning the data? And in the end, who is interpreting the data? [Smart4Diagnostics] wouldn’t have been started in this successful manner without the help of EIT Health.”

    View Smart4Diagnostics website Read Bio
  • iLof

    2018 Selected Venture

    Harnessing bio-photonics and Artificial Intelligence to unlock new possibilities in Alzheimer’s drug discovery.

    iLoF is creating a pathway which promotes breakthroughs in Alzheimer's disease research. iLoF (short for Intelligent Lab on a Fiber) it is using machine-learning to develop an non-invasive way of screening patients for clinical trials, which will accelerate the development of new and personalised Alzheimer’s treatments and make them more economically viable.

    “We all know the social tragedy behind Alzheimer’s – but the industry problem behind that is less visible. The [Wild Card] programme allowed us to study a whole industry at a deeper level and understand that in order to solve Alzheimer’s and enable a treatment, we first need precise, personalised, inexpensive tools that all stakeholders can apply. And because of that, suddenly, iLoF was born.”

    Visit iLof's website Read Bio
  • PIPRA

    2018 Selected Venture

    Revealing the risk of post-operative cognitive complications in the over-60s. Developing a powerful app that personalises pre and post-op patient care.

    Disorientation, memory loss and speech difficulties are some of the symptoms of postoperative cognitive complications in the over-60s. PIPRA, short for Pre- interventional Preventative Risk Assessment, is developing a risk score in-app intervention for pre- and post-operative patients.

    “I think we got fantastic support and guidance from people that have so many years of experience. You gain a lot, it is tremendous and pretty unique.”

    Visit PIPRA's website Read Bio
X

Who should apply

Wild Card is open to:

  • Small teams of up to five team members with a business idea, including start-ups.
  • Professionals with an entrepreneurial mindset looking to join existing teams or looking for other entrepreneurs to start a company

Other requirements

  • Applicants must hold European Union citizenship or be residents of an EU Member State and have English language proficiency
  • We expect founders selected for investment to dedicate their full working capacity to the development of the start-up as of January 2024

Meet the Wild Card team

Get updates

 

  • Get notified when the programme opens
  • Find out more about the challenge
  • Be invited to the info sessions
  • Get in contact with our team